By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

EUR 700 Million for Vienna

ground-breaking ceremony at Boehringer © Boehringer Ingelheim

The expansion drive represents the largest single investment in the history of the company, and the largest corporate investment in Vienna since the construction of the General Motors factory in Aspern in 1979. The new facility, which will be put into operation in 2021, will produce biopharmaceuticals in the future with the help of cell cultures.

“This investment comprises a sustainable commitment of the management which secures the Vienna site for decades”, says Philipp von Lattorff, Managing Director of Boehringer Ingelheim Regional Center Vienna. Up until now, Boehringer Ingelheim has produced drugs in the Austrian capital with the help of yeasts and bacteria. The new cell culture facility is a response on the part of the company to fast growing demand for biopharmaceutical drugs. As one of the world’s leading contract manufacturers in this sector, the project will help us further strengthen our market position”, explains Wolfgang Baiker, Global Head of Biopharmaceuticals and Production at Boehringer Ingelheim.

About the Boehringer Ingelheim Regional Center Vienna

The Boehringer Ingelheim Regional Center Vienna is responsible for the Boehringer Ingelheim business with prescription medications and veterinary medicines in Austria as well as in more than 30 countries in Central and Eastern Europe, Central Asia, Switzerland and Israel. In addition, all of the clinical research in the region is managed from Vienna. Vienna is the center of cancer research as well as where the Group’s biopharmaceutical research, development and production takes place. Boehringer Ingelheim is also involved in basic research at the Research Institute of Molecular Pathology (IMP) in Vienna. Boehringer Ingelheim thus ranks among the most research-intensive pharmaceutical companies in Austria. In fiscal year 2016, the Regional Center Vienna achieved total sales of EUR 821.5 million and employed 3,470 people in Central and Eastern Europe, including 1,629 in Austria. Thanks to the new production facility, the number of employees will increase to about 2,100 in the coming years.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Ukrainian-Austrian Business Forum

    27.4.2021/ 14.00 (CET) , Online Conference

  • Meet us @ Open Vienna - A Thriving Startup Ecosystem

    28.04.2021/ 9.15 am - 1.30 pm (CET), Online Conference

Austria Map

Find the perfect location for your company

Located in the heart of Europe, Austria offers an optimal base for our internationally orientated business. The great funding options as well as the support of institutions such as ABA – Invest in Austria and the Vienna Business Agency have turned out to be real USPs for the business location Austria. More and more skilled workers are drawn to Austria, because of it’s high living standard. This has helped us tremendously finding highly qualified employees for our company. We feel right at home within the steadily growing international ecosystem and easily built a network with local parties. One can feel the spirit and the will to grow into a bigger startup hub like Germany or Sweden. We hope, that by sharing our positive experiences, we can help attract more global talent to come to Austria.

Xencio

Logo: Xencio
More testimonials

news from the business location Austria

Medical University of Vienna and Vienna General Hospital: Expertise for lung transplants in cases of COVID-19

In May 2020, a team led by thoracic surgeon Konrad Hoetzenecker of the Department of Surgery of the Medical University of Vienna (MedUni Vienna) and Vienna General Hospital performed a lung transplant on a 44-year-old patient who had been seriously ill with COVID-19, making her the first patient in Europe to receive a lung transplant for this indication.

Shared Mobility in Austria!

"A green planet with mobility from everyone, for everyone" has continuously been the motto of GO Sharing.

More news All blog posts